About Us

Ardea, headquartered in San Diego, California, is a biotechnology company focused on the development of small-molecule therapeutics for the treatment of serious diseases. Ardea was formerly known as IntraBiotics Pharmaceuticals, Inc. and was incorporated in the State of Delaware in 1994.

In December 2006, we acquired intellectual property and other assets related to several classes of small-molecule therapeutics for the treatment of HIV and cancer from Valeant Research & Development, Inc., or Valeant. We have subsequently developed product candidates for the chronic management of hyperuricemia in gout patients through our own proprietary research and development efforts.

Our Business Strategy

We believe that we are well-positioned to create shareholder value given our ability to rapidly and cost-effectively advance our clinical-stage product candidates, either independently or in collaboration with pharmaceutical or other biotechnology companies.

Our most advanced clinical-stage product candidates include RDEA594, a URAT1 transporter inhibitor for the chronic management of hyperuricemia and gout, BAY 86-9766, formerly known as RDEA119, a specific inhibitor of mitogen-activated ERK kinase (MEK) for the treatment of cancer, and RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV. Further development of RDEA806 will be dependent on our ability to partner this program.